Ovarian Cancer

Snehal Bhoola, MD, discusses the implementation of enhanced recovery after surgery in ovarian cancer.

The European Commission has approved olaparib tablets (Lynparza) as a maintenance therapy for patients with platinum-sensitive relapsed high-grade, epithelial ovarian, fallopian tube or primary peritoneal cancer.

Lyndsay Willmott, MD, discusses the use of PARP inhibitors in patients with ovarian cancer and details the mechanisms of resistance that have been identified so far.

Bradley J. Monk, MD, FACOG, FACS, discusses the promise of new therapies and regimens in patients with ovarian cancer in the recurrent setting.

Matthew Borst, MD, director, GYN/Oncology, Banner Good Samaritan Regional Medical Center, clinical assistant professor of medicine, University of Arizona, Arizona Oncology, discusses homologous recombination deficiency (HRD) in patients with ovarian cancer.

Heather Dalton, MD, gynecologic oncologist, Arizona Oncology, discusses toxicities in the frontline treatment of patients with ovarian cancer.

Niraparib (Zejula) met the primary endpoint of overall response as a fourth-line or later treatment in patients with ovarian cancer, regardless of BRCA status, according to top-line results from the QUADRA study.

Shana Wingo, MD, gynecologic oncologist, Arizona Oncology, discusses surgical options for the treatment of patients with newly-diagnosed ovarian cancer.